Nuveen Asset Management LLC Has $62.97 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Nuveen Asset Management LLC lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 6.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,857,007 shares of the company's stock after purchasing an additional 182,774 shares during the period. Nuveen Asset Management LLC owned 0.25% of Teva Pharmaceutical Industries worth $62,968,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TEVA. Oarsman Capital Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $44,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $66,000. IFP Advisors Inc increased its stake in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares during the period. Finally, Quadrant Capital Group LLC lifted its position in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research analyst reports. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $24.43.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA traded down $0.21 during trading hours on Wednesday, reaching $16.58. The company had a trading volume of 12,519,318 shares, compared to its average volume of 10,006,973. The firm has a market capitalization of $18.79 billion, a PE ratio of -11.43, a PEG ratio of 1.44 and a beta of 0.62. The stock has a 50-day moving average of $15.37 and a two-hundred day moving average of $17.38. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company's revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 earnings per share. Analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.